A Leading CRO in Eastern Europe
Since 2005, OCT’s team of 130 professionals has conducted over 300 clinical trials in Eastern Europe
We've merged with Palleos Healthcare to form a wide-reaching European CRO.
Find out more
Since 2005, OCT’s team of 130 professionals has conducted over 300 clinical trials in Eastern Europe
OCT is one of the leading contract research organizations in Eastern Europe. We have conducted hundreds of clinical trials in Eastern Europe, in both CEE and the CIS. Our team of 130 professionals provides a full range of high-quality CRO services for Phase I-IV and BE studies, with therapeutic expertise in oncology, infectious diseases, and all major therapeutic indications.
As pharmaceutical and biotechnology companies have turned toward outsourcing models in clinical research, OCT has established itself as one of the top contract research organizations worldwide. With strong local expertise and focus on quality, OCT ensures seamless clinical trial conduct and drug registration, on time and within budget. Our experienced team delivers a full range of CRO services including medical writing, consultancy, project management/monitoring, data management/biostatistics and turnkey service for clinical development.
Our portfolio spans all major therapeutic areas, including oncology, infectious disease, gastroenterology, cardiology and more.
All Therapeutic Area Experience
Our journey dates back to 2005, when the founder of OCT Clinical took on a challenging case in infant respiratory distress syndrome. Back then, the mortality rate among newborns suffering from RDS was almost 100%. The Sponsor approached us with a study of surfactant, a drug administered through a lavage straight into an infant’s lungs in order to restore the collapsed airways.
In the course of the study, 2/3 of 75 infants survived, and the drug obtained marketing authorization. This was an outstanding outcome for a study of this complexity and the risks involved.
To this day, more than 300 projects later, our core values have been centered around patient safety, sponsor satisfaction and complete transparency.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.